SGHSC on SHOW
Reference: |
Drug alert |
Date Published: |
03 August 2012 |
Title: |
Immediate: ondansetron maximum single intravenous dose now restricted to 16mg to reduce the risk of qt interval prolongation and cardiac arrhythmias |
||
URL: |
|||
Description: |
The new maximum single intravenous dose of ondansetron for the management of chemotherapy-induced nausea and vomiting in adults is 16 mg (infused over at least 15 minutes). This restriction is in response to concerns raised by the results of a new study which demonstrated a dose-dependent prolongation of the electrocardiographic-corrected QT interval (QTc). |
||
Keywords: |
NHS; SCOTLAND; DRUGS; SAFETY; RISKS; PHARMACEUTICAL INDUSTRY; DRUG THERAPY; PHARMACEUTICAL SERVICES |
||
Organisation: |
Scottish Government Health and Social Care Directorates |
||
Site URL: |
|||
Contact Name: |
Irene Fazakerley |
Address: |
Pharmacy and Medicines Division, Health and Healthcare Improvement Directorate, St Andrew's House, Regent Road, Edinburgh, EH1 3DG. |
Email: |
|||
Tel: |
0131-244 2528 |
||